1093.HK CSPC Pharma (HKSE) up 8.09% to HK$9.89 on 04 Feb 2026: heavy volume signals follow-through

1093.HK stock jumped 8.09% to HK$9.89 intraday on 04 Feb 2026 on the HKSE, driven by a large trade volume of 218,580,273 shares. The move lifted price well above the 50-day average of HK$8.69 and 200-day average of HK$8.55, marking a clear short-term breakout in Hong Kong healthcare. Traders are watching whether the surge continues into the close and ahead of an earnings date set for 25 March 2026. We review volume, fundamentals, technicals, and Meyka AI model forecasts to set near-term price targets and risks for CSPC Pharmaceutical Group Limited (1093.HK)

Intraday snapshot: 1093.HK stock trading action

CSPC Pharmaceutical Group Limited (1093.HK) traded between HK$9.27 and HK$9.99 on the session, opening at HK$9.35 and closing intraday at HK$9.89. Volume hit 218,580,273 versus an average of 119,109,058, giving a relative volume of 1.84 and confirming heavy buying interest.

The share move represents a one-day change of 8.09% and lifts year-to-date performance to +16.63%. Intraday momentum indicators show RSI near 69.45, suggesting strength but approaching short-term overbought levels.

Catalysts and sector context behind the move

There is no single public catalyst in major outlets today, but elevated activity on investing platforms and sector rotation into defensive healthcare names in Hong Kong supported the jump. Recent coverage on Investing.com highlighted renewed investor attention on CSPC source and live quote traffic suggests increased retail and institutional flows source.

Healthcare in Hong Kong has been modestly outperforming peers this month. CSPC sits in the Drug Manufacturers – General industry where investors reward stable margins and dividend yield, which likely amplified interest during today’s session.

Fundamentals snapshot and valuation for 1093.HK stock

CSPC reports EPS of HK$0.38 and a trailing P/E of 26.03 based on the current price of HK$9.89. Market capitalisation stands at HK$112,968,047,629 and dividend per share is HK$0.213, a yield of about 2.43%. Key ratios include price-to-sales 3.68, price-to-book 3.02, and free cash flow yield 1.48%.

Profitability remains solid: gross margin 66.72%, operating margin 16.35%, and return on equity 12.42%. Balance-sheet metrics show low leverage with debt-to-equity 0.01 and current ratio 2.24, giving the company defensive credit characteristics ahead of the March earnings.

Technical setup, indicators and price targets for 1093.HK stock

Technically, the stock cleared its 50- and 200-day moving averages and printed a session high near HK$9.99. Momentum indicators show MACD histogram positive and ADX at 28.79, indicating a strong short-term trend. Volatility is moderate with ATR HK$0.34.

Analyst-style targets: a near-term resistance test at HK$10.50 (first target) and a bullish scenario target at HK$12.00 (secondary). A failure to hold HK$9.27 intraday would shift focus to support near HK$8.34 (Bollinger middle). Use stop discipline given MFI 83.97 and stochastic readings above 93, both signaling overbought risk.

Meyka AI rating and model forecast for 1093.HK stock

Meyka AI rates 1093.HK with a score of 67.36 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The in-house rating balances strong margins and cash metrics against slower recent earnings growth.

Meyka AI’s forecast model projects a monthly price of HK$10.94, a quarterly price of HK$10.31, and a 12-month target of HK$11.74. Versus the current price of HK$9.89, the 12-month projection implies an upside of 18.74% and the monthly projection implies 10.62%. Forecasts are model-based projections and not guarantees.

Risks, catalysts and trading strategy for most active traders

Key risks include weaker-than-expected FY2025 earnings (next announcement 25 March 2026), regulatory changes in China, and short-term profit taking after a strong intraday run. Receivables days are long at 126.56, which could pressure cash conversion if sales slow.

For intraday and short-term active traders: monitor volume continuation above 150 million and whether price sustains above HK$9.80. A momentum entry with a tight stop near HK$9.25 suits traders seeking swing exposure. Longer-term investors should weigh valuation at P/E 26.03 against growth trends and dividend yield.

Final Thoughts

Today’s intraday surge makes 1093.HK stock one of Hong Kong’s most active healthcare names, rising 8.09% to HK$9.89 on heavy volume of 218,580,273 shares. Fundamentals remain solid: EPS HK$0.38, P/E 26.03, return on equity 12.42%, and a dividend yield near 2.43%. Meyka AI rates the stock 67.36/100 (B, HOLD) and forecasts HK$11.74 in 12 months, implying +18.74% upside from today’s price. Short-term technical targets are HK$10.50 and HK$12.00, but indicators show overbought readings, so traders should manage risk. We recommend watching intraday volume and the upcoming 25 March 2026 earnings for confirmation. Meyka AI, an AI-powered market analysis platform, provides these model-based insights but forecasts are projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.